ILSUNG IS CO., LTD.

003120· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩20,750-1.89%

2026-11-02

Financials

Valuation Metrics

ILSUNG IS CO., LTD.'s Market Cap is ₩2208B. At end of 2025 it was ₩2320B. Ranked #755 of 2,405 in KR market (top 31%), #421 of 778 on KOSPI (top 54%), #82 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	220.78B KRW	KR#755/2,405 Sec#82/231
Revenue	65.22B KRW	KR#1,646/2,405 Sec#108/231
Net Income	5.54B KRW	KR#1,168/2,405 Sec#75/231
Total Assets	403.01B KRW	KR#881/2,405 Sec#52/231
Net Assets	386.34B KRW	KR#605/2,405 Sec#38/231
Employees	200	KR#1,105/2,405 Sec#91/231
Value
P/E	39.84x	KR#1,383/2,405 Sec#87/231
P/B	0.57x	KR#1,010/2,405 Sec#56/231
P/S	3.39x	KR#2,041/2,405 Sec#130/231
FCF Yield	0.79%	KR#1,162/2,405 Sec#87/231
Profitability
ROE	1.43%	KR#1,452/2,405 Sec#100/231
ROA	1.38%	KR#1,338/2,405 Sec#96/231
Op. Margin	-7.53%	KR#1,925/2,405 Sec#130/231
Revenue Growth	-5.16%	KR#1,769/2,405 Sec#170/231
Earnings Growth	-52.22%	KR#1,062/2,405 Sec#72/231
Financial Health
Debt Ratio	4.31%	KR#24/2,405 Sec#9/231
Total Debt	0 KRW	KR—/2,405 Sec—/231
FCF	1.75B KRW	KR#1,099/2,405 Sec#79/231
Cash	120.28B KRW	KR#408/2,405 Sec#19/231
Current Ratio	20.42x	KR#25/2,405 Sec#11/231
Dividend
Div. Yield	5.80%	KR#229/2,405 Sec#6/231
Div. Growth	20.00%	KR#436/2,405 Sec#23/231
Performance
1Y Return	-9.78%	KR#836/2,405 Sec#48/231
1M Return	-5.90%	KR#793/2,405 Sec#76/231
From 52W High	-29.18%	KR#393/2,405 Sec#26/231
1Y MDD	-35.34%	KR#400/2,405 Sec#27/231
Trading
Volume	10,622 shares	KR#1,813/2,405 Sec#176/231
Trading Value	218.1M KRW	KR#1,096/2,405 Sec#123/231
Foreign Own.	0.38%	KR#2,228/2,405 Sec#215/231
Per Share
EPS	521 KRW	KR#978/2,405 Sec#71/231
BPS	36,311 KRW	KR#323/2,405 Sec#19/231

Company Info

CEO 윤석근, 엄대식, 윤종호(각자대표)

Employees 200

Founded 1961

HQ 서울특별시 용산구, KR

Website www.ilsungis.com

동사는 1954년 설립되어 1961년 일성신약으로 공식 출범하고 1985년 거래소시장에 상장됨. 글락소스미스클라인(GSK)과 협력해 항생제 분야를 특화하여 세계적 수준의 페니실린 항생제를 생산 중이며, 오구멘틴은 13,366백만원 매출을 기록하고 일본 등 해외에 수출하고 있음. 인간존중 사상을 바탕으로 건강한 삶을 위해 의약품 연구개발에 노력하고, 국내외 대학과 산학협력을 통한 공동 연구를 진행하고 있음. 일성아이에스는 1961년에 설립되었으며 서울특별시 용산구에 본사를 두고 있습니다.